A recent JAMA study from University of Texas MD Anderson Cancer Center researchers found no correlation between intensity of post-treatment surveillance and detection of recurrence or survival in patients with stage I, II or III colorectal cancer (CRC).

Two hospitals in East Africa have announced participation in the American College of Cardiology’s CathPCI registry, which aims to assess treatments and outcomes related to cardiac catheterization and percutaneous coronary interventions (PCIs).

In a May 20 essay in the Washington Post, Steven Petrow takes a look at his sister’s battle with ovarian cancer. He described how, after 18 weeks of chemotherapy, she is faced with a decision: Enroll in clinical trials or sit back in and opt for “active surveillance.”

Of the 247 emergency room (ER) physicians who responded to the ACEP poll, only 6 percent said their department is “completely” prepared for surge capacity in the wake of a disaster or mass casualty incident.

Researchers have successfully used robot-assisted multispectral-fluorescence imaging to distinguish between healthy and diseased lymphatic flow patterns.

Researchers at the North Carolina State University and the University of North Carolina at Chapel Hill have developed a technology capable of decoding neuromuscular signals to improve the control of powered prosthetic wrists and hands.

New research has found fetal MRI can reliably identify holoprosencephaly as early as 18 weeks into pregnancy, providing added time for parents to understand and prepare for the condition.

PARIS, May 22, 2018 — HeartFlow, Inc. today announced new data from the PACIFIC trial showed that the HeartFlow Analysis had the highest diagnostic performance for detecting coronary artery disease (CAD), the most common form of heart disease, when compared to other commonly used non-invasive cardiac tests.

Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) was associated with a 54 percent reduction in the composite endpoint of death, myocardial infarction and urgent revascularization when compared to medical therapy alone, according to five-year data from the FAME 2 trial.

NSW Health in Australia has signed a Proof of Concept agreement with the international medical imaging IT and cybersecurity company Sectra (STO: SECT B), which has been selected as the preferred vendor for a large enterprise imaging IT solution in New South Wales following a competitive tender process.